CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 110 enrolled
Drug / intervention
Etonogestrel (ETG) implant +3 moredrug
Likely dose
Etonogestrel (ETG) implant 68 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04669678
NCT04669678Phase 4Completed

An Observational Pharmacokinetic Study to Evaluate Drug-drug Interactions Between Doravirine-containing ART and Hormonal Contraceptives Among Women Living With HIV in South Africa.

University of Alabama at Birmingham·interventional·Posted Dec 17, 2020·Updated Apr 8, 2025

In Brief

A Phase 4 clinical trial evaluating Etonogestrel (ETG) implant, Intramuscular depo-medroxyprogesterone acetate (IM DMPA), and 2 other interventions for HIV Infections and 2 related conditions. Completed, enrolled 110 participants across 1 site.

Detailed Summary

The study investigators are conducting an observational, parallel group pharmacokinetic (PK) study among women living with HIV (WLHIV) already on 1st line antiretroviral therapy (ART) and virally suppressed, 18-45 years old (inclusive), to evaluate any bidirectional drug-drug interactions (DDIs) between doravirine (DOR)-containing ART and hormonal contraceptive methods. This PK study will enroll women in five distinct groups, each with 21 participants (total of 105 participants), and follow them for approximately 18-30 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Africa

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedDec 17, 2020
Enrollment StartNov 17, 2021
Primary CompletionFeb 5, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 5.5 years ago

Interventions

Etonogestrel (ETG) implantdrug

Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm. The most widely available implant in South Africa is currently Implanon®/Nexplanon®/Implanon NXT®, containing etonogestrel (ETG, 3-keto desogestrel). Implanon® consists of a single rod of ethylene vinyl acetate and contains 68 mg of ETG; it is manufactured by Merck and is approved for 3 years.

Intramuscular depo-medroxyprogesterone acetate (IM DMPA)drug

DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide, and the most commonly used method of reversible injectable contraception in sub-Saharan Africa.

Sub-cutaneous medroxyprogesterone acetate (SC MPA)drug

SC MPA or Sayana® Press is a single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection. Sayana® Press is indicated for medium-long term female contraception.

Non-hormonal intrauterine device (IUD)device

The NOVA T-380 non-hormonal IUD consists of a T-shaped polyethylene frame wound with copper wire, along with two monofilament threads to aid in removal of the IUD. IUDs may be left in place for up to 5 years.